• Ustekinumab, TNF inhibitors exhibit comparable 3-year persistence in psoriatic arthritis

    9 days ago - By Healio

    Ustekinumab and TNF inhibitors demonstrate comparably persistent effects at 3 years in patients with psoriatic arthritis, but with fewer adverse events in those receiving ustekinumab, according to data.
    “The ultimate goal of PsA therapy is to achieve the lowest possible disease activity, defined by composite measures such as the clinical Disease Activity Index for PSA and minimal disease activity/very low disease activity ,” Laure Gossec, MD, PhD, of Sorbonne University and Pitié-Salpêtrière Hospital, in Paris, and colleagues wrote in the Annals of the Rheumatic
    Read more ...